Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open flat
Wed, 11 Jan 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in Taiwan (up 0.3%) and Singapore (up 0.2%) trading firm. However, markets in China (down 0.4%) and South Korea (down 0.3%) are facing selling pressure. The Indian stock markets have opened the day on a flat note. Stocks in the realty and metal sectors are trading n the green.

The BSE-Sensex is trading marginally higher by 7 points (0.04%), while the NSE-Nifty is up by around 5 points (0.1%). Mid cap and small cap stocks are trading in the green with the BSE Mid cap and BSE Small cap indices up by 0.5% and 0.6% respectively. The rupee is trading at 52.98 to the US dollar.

Pharma Stocks have opened the day on a mixed note with Dishman Pharma, Ranbaxy Laboratories and Lupin trading in the red. However, Indoco Remedies and Biocon are trading firm. India's premier biotech company, Biocon, announced positive results for treat-plaq study with Itolizumab in chronic plaque psoriasis (skin related disease). The company came out with a press release stating that its double blind, placebo controlled, phase III treat-Plaq study of the first humanised anti CD-6 monoclonal antibody, successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score. Many other secondary end-points were also met by the trials after 12 and 28 weeks of treatment. The Chairman of Biocon commented that Itolizumab has shown significant advancement in the treatment of psoriasis. If the success of the phase III trials goes in a similar manner, this can well become India's first novel discovery of biologic.

Auto Stocks have opened the day on a mixed note with Ashok Leyland and Tata Motors trading in the green. However, Mahindra & Mahindra (M&M) is facing selling pressure. TVS Motor has announced that it will re-launch one of its best selling motorcycles 'Victor' in India in December 2012. The two-wheeler maker had discontinued the Victor four years back and the same was replaced by Centra. However, the company believes that Victor still has a lot of consumer demand. TVS also plans to introduce three more products in 2012. It is planning a capex of Rs 1.25 bn for the financial year 2012-13 (FY13). The company is also considering an increase in its overall production capacity to about 32 lakh units annually by 2013-14 (FY14). For this, it may have to invest an additional sum of about Rs 1.6 bn.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.